Laurus Labs Limited has informed the Exchange regarding a press release dated July 25, 2025, titled "Laurus Labs Announces Q1 FY26 Results".
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Laurus Labs reported a strong Q1 FY26 with consolidated revenues of ₹1,570 Cr, up 31% year-on-year from ₹1,195 Cr. EBITDA jumped 127% to ₹389 Cr, with margins expanding sharply to 24.8% from 14.3%, helped by operating leverage and a favourable CDMO mix. Net profit surged 1,154% to ₹163 Cr (from just ₹13 Cr a year ago), and EPS rose to ₹3.0 from ₹0.2. The CDMO segment was the standout, growing 103% to ₹522 Cr, led by a 130% jump in small molecules, while the Generics business grew 12% to ₹1,048 Cr with FDF (finished dosage) up 50%. The company also began construction on a new Gene/ADC facility in Hyderabad and a microbial fermentation unit in Vizag, and completed 39 quality audits in the quarter.
This is a clearly positive earnings print for shareholders, with revenue growth, margin expansion, and profit growth all running well ahead of last year, likely to support a positive reaction in the stock. The strong CDMO momentum and capacity build-out signal management's confidence in multi-year growth, though the Bio sub-segment decline (-33%) and API softness (-4%) are minor watch-points.